Nilotinib Accord

Nilotinib, the active ingredient in Nilotinib Accord, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively blocks the BCR‑ABL enzyme, thereby treating chronic myeloid leukemia in adult patients who have the Philadelphia chromosome abnormality.

GNH USA supplies Nilotinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, providing reliable sourcing, regulatory documentation and logistics support for qualified healthcare institutions across multiple regions and therapeutic areas.

Nilotinib is a targeted therapy used in the treatment of chronic myeloid leukemia, a disease driven by the BCR‑ABL tyrosine kinase.

Chronic myeloid leukemia (chronic phase): reduces disease progression and improves survival in adult patients with Philadelphia chromosome‑positive CML. Accelerated phase CML: helps achieve hematologic and cytogenetic responses in patients whose disease has progressed. Blast phase CML: provides disease control when combined with other agents in advanced disease stages.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be watery. - Rash: skin redness or irritation. - Fatigue: feeling unusually tired. - Headache: mild to moderate head pain. - Muscle cramps: involuntary tightening of muscles.

Serious or Rare Side Effects: - QT prolongation: heart rhythm disturbance that can lead to arrhythmia. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Severe neutropenia: dangerously low white blood cell count increasing infection risk. - Thrombocytopenia: low platelet count causing bleeding tendencies. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly. - Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT‑interval risk. - Liver function: check hepatic enzymes before and during treatment. - Hematologic surveillance: monitor complete blood counts for neutropenia and thrombocytopenia. - Drug interactions: avoid strong CYP3A4 inhibitors that can raise nilotinib levels. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib plasma concentrations. - QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias. - Antacids or proton‑pump inhibitors that raise gastric pH: can reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, St. John’s wort): may lower nilotinib exposure. - Anticoagulants (e.g., warfarin): may require INR monitoring. - Statins (e.g., simvastatin, atorvastatin): may have increased plasma concentrations and need dose adjustment.